[Ip-health] EndPoints: Covid-19 roundup: BARDA hands AstraZeneca $1B-plus to race through PhIII and ramp up fall deliveries of Oxford’s pandemic vaccine – Endpoints News
Damiano de Felice
ddefelice at accesstomedicinefoundation.org
Thu May 21 10:29:53 PDT 2020
Interesting part of the press release:
“Today’s announcement is not anticipated to have any significant impact on
the Company’s financial guidance for 2020; expenses to progress the vaccine
are anticipated to be offset by funding by governments.”
On Thu, 21 May 2020 at 18:53, James Love <james.love at keionline.org> wrote:
> This is the company press release.
> AstraZeneca today received support of more than $1bn from the US Biomedical
> Advanced Research and Development Authority (BARDA) for the development,
> production and delivery of the vaccine, starting in the fall. The
> development programme includes a Phase III clinical trial with 30,000
> participants and a paediatric trial.
> In addition, the Company is engaging with international organisations such
> as the Coalition for Epidemic Preparedness Innovations (CEPI), Gavi the
> Vaccine Alliance and the World Health Organisation (WHO), for the fair
> allocation and distribution of the vaccine around the world. AstraZeneca is
> also in discussions with governments around the world to increase access.
> Furthermore, AstraZeneca is in discussions with the Serum Institute of
> India and other potential partners to increase production and distribution.
> AstraZeneca recently joined forces with the UK Government to support Oxford
> University’s vaccine and has progressed rapidly in its efforts to expand
> access around the world. The Company will supply the UK starting in
> September and is thankful for the Government’s commitment and overall work
> on vaccines.
> Pascal Soriot, Chief Executive Officer, said: “This pandemic is a global
> tragedy and it is a challenge for all of humanity. We need to defeat the
> virus together or it will continue to inflict huge personal suffering and
> leave long-lasting economic and social scars in every country around the
> world. We are so proud to be collaborating with Oxford University to turn
> their ground-breaking work into a medicine that can be produced on a global
> scale. We would like to thank the US and UK governments for their
> substantial support to accelerate the development and production of the
> vaccine. We will do everything in our power to make this vaccine quickly
> and widely available.”
> AstraZeneca has now finalised its licence agreement with Oxford University
> for the recombinant adenovirus vaccine. The licensing of the vaccine,
> formerly ChAdOx1 nCoV-19 and now known as AZD1222, follows the recent
> global development and distribution agreement with the University’s Jenner
> Institute and the Oxford Vaccine Group. AstraZeneca has also agreed to
> support the establishment of a joint research centre at Oxford University
> for pandemic preparedness research.
> . . .
> On Thu, May 21, 2020 at 7:47 AM James Love <james.love at keionline.org>
> > Another massive US government grant.contract on vaccine development.,
> > this one to AstraZeneca. Could explain why UK was working with US to
> > oppose strong open licensing language at the WHA. (just as the Moderna
> > contracts for Swiss manufacturing shed light on the Swiss position).
> > Jamie
> > Covid-19 roundup: BARDA hands AstraZeneca $1B-plus to race through PhIII
> > and ramp up fall deliveries of Oxford’s pandemic vaccine – Endpoints News
> > Natalie Grover
> > Allied with researchers at Oxford University on one of the leading
> > vaccines now in development for Covid-19, AstraZeneca reported that it
> > secured more than $1 billion from BARDA for the development, production
> > delivery of the vaccine, starting in the fall. The injection dwarfs the
> > additional £84 million ($102 million) in funding for 30 million doses (up
> > to 100 million doses) from the United Kingdom, which envisions
> > at least half its population by September.
> James Love. Knowledge Ecology International
> U.S. Mobile +1.202.361.3040
> U.S. office phone +1.202.332.2670
> http://www.keionline.org <http://www.keionline.org/donate.html>
> Ip-health mailing list
> Ip-health at lists.keionline.org
Sent from mobile
More information about the Ip-health